QuidelOrtho Corporation

Equities

QDEL

US2197981051

Market Closed - Nasdaq Other stock markets 21:00:00 14/01/2026 GMT			5-day change	1st Jan Change
34.34 ^USD	+3.12%		+2.91%	+20.24%

12-03	QuidelOrtho Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:00 PM
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT

Transcript : QuidelOrtho Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01

Published on 12/03/2025 at 07:20 pm GMT - Modified on 12/03/2025 at 09:06 pm GMT

S&P Capital IQ

Presenter Speech
Patrick Donnelly (Analysts)

We can look to get started. Thank you for joining us. I'm Patrick Donnelly, the tools and diagnostics analyst here at Citi. Happy to have Joe Busky, here

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about QuidelOrtho Corporation

12-03	QuidelOrtho Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:00 PM
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT
11-06	QuidelOrtho Corporation, Q3 2025 Earnings Call, Nov 05, 2025
11-05	In vitro diagnostics firm QuidelOrtho beats Q3 revenue expectations	RE
11-05	Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q3 Revenue $699.9M, vs. FactSet Est of $664.9M	MT
11-05	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q3 Adjusted EPS $0.80 per Share, vs. FactSet Est of $0.46	MT
11-05	QuidelOrtho Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 28, 2025	CI
11-05	Quidelortho Corporation Provides Earnings Guidance for Full Year 2025	CI
11-03	QuidelOrtho Receives FDA 510(k) Clearance for VITROS?? Immunodiagnostic Products hs Troponin I Assay	CI
11-03	QuidelOrtho Gets FDA Clearance for Cardiac Assay	MT
11-03	Quidelortho receives FDA 510(k) clearance for VITROS Immunodiagnostic Products hs Troponin I assay	RE
07/10/25	Citigroup Downgrades QuidelOrtho to Neutral From Buy, Adjusts Price Target to $33 From $40	MT
22/09/25	QuidelOrtho Corporation Announces Availability of QuICKVUE Influenza + SARS Test for Professional Use	CI
03/09/25	RBC Raises Price Target on QuidelOrtho to $62 From $60, Keeps Outperform Rating	MT
21/08/25	QuidelOrtho completes debt refinancing	RE
21/08/25	QuidelOrtho Completes $3.4 Billion in Debt Refinancing	MT
21/08/25	QuidelOrtho Corporation Enters into a Credit Agreement	CI
19/08/25	Quidelortho welcomes Erich Wolff as EVP, strategy & corporate development	RE
19/08/25	QuidelOrtho Corporation Appoints Erich Wolff as Executive Vice President, Strategy & Corporate Development	CI
13/08/25	QuidelOrtho Corporation Launches Certified Analyzer Program to Enhance Diagnostic Testing Access in Rural Hospitals	CI
07/08/25	UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating	MT
06/08/25	QuidelOrtho Fiscal Q2 Swings to Adjusted Earnings, Revenue Falls	MT
06/08/25	QuidelOrtho Corporation, Q2 2025 Earnings Call, Aug 05, 2025
05/08/25	QuidelOrtho Q2 revenue falls but beats expectations	RE
05/08/25	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q2 Adjusted EPS $0.12 per Share, vs. FactSet Est of $0.00	MT